Automated report. This article was drafted with AI assistance from the sources listed below, without a human writing step. Law Week labels every article produced this way. A person is answerable for it: if something here is wrong, write to editor@law-week.com and we will correct it on the page and say what changed.
Wedlake Bell said in an announcement on its website on 3 November 2026 that it had advised the shareholders of Estima Scientific Ltd on the sale of the company’s entire issued share capital to EVERSANA.
Key points
- Wedlake Bell said it acted for the shareholders of Estima Scientific Ltd on the sale of the company’s entire issued share capital to EVERSANA.
- Corporate partner Nigel Taylor led the firm’s M&A team, according to the announcement.
- The firm said specialists in corporate tax, employment, and IP and commercial law also worked on the deal.
The companies
The announcement describes Estima Scientific as a London-based health economics and outcomes research (HEOR) technology and services company. According to Wedlake Bell, it pairs specialist consulting with its own AI-powered software to help pharmaceutical and biotechnology companies show the therapeutic value of their products to payers and health technology assessment bodies around the world.
EVERSANA is described in the announcement as an independent provider of commercialisation services to the biopharmaceutical industry, working across every stage of a product’s life cycle. The announcement says it serves more than 650 organisations, from start-ups to established pharmaceutical companies.
The Wedlake Bell team
According to the firm, Nigel Taylor, a corporate partner, led the team. He was supported by senior associates James French and Tom Boersma and solicitor Enea Aniaj, all from the corporate team. Partner Mike Ridsdale and solicitor Lucy Foster handled corporate tax, legal director Choy Lau handled employment, and partner Adam Betts and solicitor Emma Thomas handled IP and commercial matters, the firm said.
What they said
Tim Reason, co-founder of Estima Scientific, said: “We are delighted to have completed the sale of Estima Scientific to Eversana. The Wedlake Bell team provided clear, pragmatic advice throughout the process and were instrumental in helping us navigate the transaction and bring it to a successful conclusion. We are very grateful to Nigel, James, Tom and Enea, as well as the wider team for their commitment and support.”
Nigel Taylor, Corporate Partner at Wedlake Bell, said: “We are delighted to have advised on the sale of Estima Scientific to Eversana. It has been a real pleasure working with Tim, Andy and the wider team throughout the process. This was an important transaction for all involved, and we are very pleased to have helped bring it to a successful conclusion. We wish the business every success for the next stage of its development.”